{"DataElement":{"publicId":"6161748","version":"1","preferredName":"Acute Myeloid Leukemia Myelodysplastic Syndrome Cytogenetic Response Status","preferredDefinition":"Text term to describe the status of acute myeloid leukemia and myelodysplastic syndrome based on cytogenetic evaluation.","longName":"AML_MDS_CYT_RESP_STAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6161745","version":"1","preferredName":"Acute Myeloid Leukemia Myelodysplastic Syndrome Disease Response Cytogenetic Analysis Evaluation","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)_The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"6161743v1.0:3853590v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"6161743","version":"1","preferredName":"Acute Myeloid Leukemia Myelodysplastic Syndrome Disease Response","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C3171:C3247:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69211105-B75C-3FE9-E053-F662850AB708","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853590","version":"1","preferredName":"Cytogenetic Analysis Evaluation","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C18280:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D0EF-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69211105-B76A-3FE9-E053-F662850AB708","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"SOKKERL","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6161746","version":"1","preferredName":"CML (AP) Cytogenetic Analysis Response Status","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"CMLAP_CYTGN_RSP_ST","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69215A3F-7816-58D3-E053-F662850AC194","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"HP","valueDescription":"Persistent disease (Hematologic persistence)","ValueMeaning":{"publicId":"3178994","version":"1","preferredName":"Persistent disease (Hematologic persistence)","longName":"3178994","preferredDefinition":"A disease that does not go to remission despite treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Persistent Disease","conceptCode":"C90169","definition":"A disease that does not go to remission despite treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4AE1-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"SOKKERL","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"69215A3F-780C-58D3-E053-F662850AC194","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"CCyR","valueDescription":"Cytogenetic Analysis Complete Remission","ValueMeaning":{"publicId":"3854980","version":"1","preferredName":"Cytogenetic Analysis Complete Remission","longName":"3854980","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-882B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SOKKERL","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"692EB91F-9564-10EC-E053-F662850A4C82","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"NCyR","valueDescription":"No Cytogenetic Analysis Remission","ValueMeaning":{"publicId":"3854983","version":"1","preferredName":"No Cytogenetic Analysis Remission","longName":"3854983","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-88D0-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930F182-1B91-0AB9-E053-F662850A0E93","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"NA","valueDescription":"No Assessment","ValueMeaning":{"publicId":"2768467","version":"1","preferredName":"No Assessment","longName":"2768467","preferredDefinition":"The non-affirmative response to a question.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52C71733-4814-2BF1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930F182-1BA7-0AB9-E053-F662850A0E93","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930F182-1BB1-0AB9-E053-F662850A0E93","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"PCyR","valueDescription":"Cytogenetic Analysis Partial Remission","ValueMeaning":{"publicId":"3854987","version":"1","preferredName":"Cytogenetic Analysis Partial Remission","longName":"3854987","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-896B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930F182-1BC5-0AB9-E053-F662850A0E93","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"MCyR","valueDescription":"Major Cytogenetic Analysis Remission","ValueMeaning":{"publicId":"3854986","version":"1","preferredName":"Major Cytogenetic Analysis Remission","longName":"3854986","preferredDefinition":"Greater or bigger in amount, extent, or size.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Major","conceptCode":"C45368","definition":"Greater or bigger in amount, extent, or size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-8945-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930D812-7C76-0ABD-E053-F662850AEC4E","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"MinCyR","valueDescription":"Minimum Cytogenetic Analysis Remission","ValueMeaning":{"publicId":"3854984","version":"1","preferredName":"Minimum Cytogenetic Analysis Remission","longName":"3854984","preferredDefinition":"The smallest possible quantity.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimum","conceptCode":"C25570","definition":"The smallest possible quantity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-88F7-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930D812-7C8C-0ABD-E053-F662850AEC4E","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"MiCyR","valueDescription":"Minor Cytogenetic Analysis Remission","ValueMeaning":{"publicId":"3854985","version":"1","preferredName":"Minor Cytogenetic Analysis Remission","longName":"3854985","preferredDefinition":"Lesser or smaller in amount, extent, or size.: Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minor","conceptCode":"C45367","definition":"Lesser or smaller in amount, extent, or size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-891E-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6930EA6B-16F8-0AB1-E053-F662850A3415","beginDate":"2013-08-13","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-06","modifiedBy":"ONEDATA","dateModified":"2018-04-06","deletedIndicator":"No"},{"value":"Cytogenetic Analysis Not Complete Remission","valueDescription":"Cytogenetic Analysis Negation Complete Remission","ValueMeaning":{"publicId":"6618517","version":"1","preferredName":"Cytogenetic Analysis Negation Complete Remission","longName":"6618517","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: An operation in which a term denies or inverts the meaning of another term or construction.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8034EA61-09F3-1B02-E053-F662850AA473","latestVersionIndicator":"Yes","beginDate":"2019-01-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-24","modifiedBy":"ONEDATA","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94551A0D-1072-197D-E053-F662850ABC1E","beginDate":"2019-10-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-07","modifiedBy":"ONEDATA","dateModified":"2019-10-07","deletedIndicator":"No"},{"value":"Cytogenetic Analysis Omitted or Failed","valueDescription":"Cytogenetic Analysis Omitted or Failed","ValueMeaning":{"publicId":"6972847","version":"1","preferredName":"Cytogenetic Analysis Omitted or Failed","longName":"6972847","preferredDefinition":"Cytogenetic Analysis Omitted or Failed","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94551A0D-107D-197D-E053-F662850ABC1E","latestVersionIndicator":"Yes","beginDate":"2019-10-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-07","modifiedBy":"ONEDATA","dateModified":"2019-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94551A0D-1096-197D-E053-F662850ABC1E","beginDate":"2019-10-07","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-10-07","modifiedBy":"ONEDATA","dateModified":"2019-10-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865326","version":"1","preferredName":"Cytogenetic Analysis Response Status","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C18280:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F25E-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69215A3F-77E0-58D3-E053-F662850AC194","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"SOKKERL","dateModified":"2019-10-07","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Cytogenic Response","type":"Preferred Question Text","description":"Cytogenic Response","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Cytogenic results","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Cytogenetic Status","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6921214A-EA4F-4250-E053-F662850ACE3F","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-04-05","modifiedBy":"SOKKERL","dateModified":"2019-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}